Novel Immunotherapy Combination Appears Effective in Patients with Metastatic Pancreatic Cancer

TOP - March 2022 Vol 15, No 2 - ASCO

Interim results from a phase 2 clinical trial showed that a novel combination of aldoxorubicin, N-803 (an IL-15 superagonist), and PD-L1 natural killer cell therapy (Nant Cancer Vaccine) plus low-dose chemotherapy doubled overall survival (OS) compared with historical controls in patients with locally advanced or metastatic pancreatic cancer.

The QUILT-88 trial demonstrated a median OS of 6.3 months (95% confidence interval [CI], 5.0-9.8 months) among patients who had progressed after 2 previous lines of therapy, according to Tara Seery, MD, Co-Director, Cellular Therapy Research, and Medical Oncologist, Hoag Cancer Center, Newport Beach, CA, and colleagues, who reported the findings in a poster presentation at the 2022 ASCO Gastrointestinal Cancers Symposium.

When patients with more advanced disease, who had been treated with 4 to 6 previous lines of therapy, were added to the data set (N = 61), the median OS of the entire cohort was 5.8 months (95% CI, 3.9-6.9).

The vaccine was designed to be administered in an outpatient setting, perhaps making it more accessible to future patients than traditional immune checkpoint inhibitors, said Patrick Soon-Shiong, MD, Global Chief Scientific and Medical Officer, ImmunityBio, in a press release.

“Pancreatic cancer claimed an estimated 47,050 lives in the USA in 2020, with an expected 5-year survival of 10%. In patients with advanced disease (>3rd line), the median OS is 3 months. Thus, there is an urgent need for novel treatment options in this disease,” Dr Seery and colleagues noted. “We hypothesize that effective response against pancreatic cancer requires a coordinated approach that orchestrates both the innate and adaptive immune system. We further hypothesize that by orchestrating the activation of the entire immune system, we could accomplish immunogenic cell death with durable responses in this disease.”

Study Details

The phase 2, open-label QUILT-88 trial evaluated the efficacy and safety of the Nant Cancer Vaccine following low-dose chemoradiation therapy (nab-paclitaxel [Abraxane; 100 mg/m2 intravenously], gemcitabine [Gemzar; 600 mg/m2 intravenously], cyclophosphamide [50 mg orally twice daily]), and low-dose stereotactic body radiation therapy.

The patients’ median age was 62 years, and 62% were male; 93% had metastatic disease. Of the 63 patients enrolled in the trial, 30 (48%) had disease progression after 2 previous lines of therapy. As of data cutoff, patients have been followed for a median of 3.9 months.

At 3 months, 44 patients were evaluable, and in this group, the OS was 81.8% (95% CI, 67.3%-91.8%). Median OS was not yet reached. The median progression-free survival was 2.4 months (95% CI, 2.0-3.7). The disease control rate in 47 evaluable patients was 36.2% (95% CI, 22.7%-51.5%).

To date, 27% of third-line or greater patients (17 of 63) remain on study, with 14 months as the longest duration on therapy at data cutoff.

Treatment-related serious adverse events were uncommon, and no treatment-related deaths were reported. Forty-one (75%) patients experienced grade ≥3 adverse events related to chemotherapy, including anemia in 44%, neutropenia in 24%, and thrombocytopenia in 11%. Five (9%) patients had serious adverse events.

Future Studies

The investigators are independently evaluating 3 cohorts of patients, in the first- and second-line or later maintenance treatment settings, labeled cohorts A, B, and C, respectively. Cohorts A and B have independent experimental and control arms. The study is expected to enroll 328 patients across all 3 cohorts. In cohort C, as reported in the poster, 63 of an expected total of 80 patients have been enrolled, with assessment of OS as the primary objective.

ImmunityBio announced that it plans to meet with the FDA in 2022 to discuss the path for the approval of combination therapies for pancreatic cancer.

Related Items
Updated NCCN Guidelines Lower Age for Initial Colorectal Cancer Screening
William King
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in NCCN 2022 Highlights
Pembrolizumab Added to Best Supportive Care Extends Survival in Patients with Hepatocellular Carcinoma
William King
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in ASCO GI 2022 Highlights
Nivolumab plus Ipilimumab Yields High Rate of pCR in the Neoadjuvant Setting for Patients with Resectable MSI/dMMR Oeso-Gastric Adenocarcinoma
William King
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in ASCO GI 2022 Highlights
Trastuzumab Deruxtecan Shows Survival Benefit in HER2-Positive Advanced Gastric Cancers
William King
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in ASCO GI 2022 Highlights
Continuous Treatment with Enzalutamide and Docetaxel Reduces the Risk for Progression in Patients with Metastatic Castration-Resistant Prostate Cancer
William King
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in ASCO GU 2022 Highlights
Neoadjuvant Enfortumab Vedotin Therapy Promising in Patients with Cisplatin-Ineligible Muscle-Invasive Bladder Cancer
William King
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in ASCO GU 2022 Highlights
New Treatment Strategies for Patients with Advanced Melanoma
William King
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in NCCN 2022 Highlights
The Future of Genetic Therapies and Value-Based Care in Oncology
William King
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in AVBCC Summit Highlights
Community Provider Perspective: The Current and Future State of Cancer Care
William King
TOP - May 2022 Vol 15, No 3 published on May 6, 2022 in AVBCC Summit Highlights
Biosimilars and the Road Ahead: Experts Discuss Opportunities and Challenges
William King
TOP - March 2022 Vol 15, No 2 published on March 16, 2022 in AVBCC Summit Highlights
Last modified: March 18, 2022